Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 16, No 5 (2020) Pharmacokinetics and Pharmacogenetics of Apixaban Abstract  similar documents
A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova
"... . The hypothesis about CYP и SULT1A enzymes influence on apixaban metabolism was examined. To date, numerous SNVs ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..."
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
 
Vol 10, No 3 (2014) EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION Abstract  similar documents
"... European Medicines Agency approved apixaban use in cardioversion. ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..."
 
Vol 16, No 2 (2020) The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..."
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
 
Vol 16, No 1 (2020) Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice Abstract  similar documents
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 16, No 1 (2020) The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation Abstract  similar documents
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva
"... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..."
 
Vol 16, No 2 (2020) Off-Label Medicines Use: Complex Problem of Modern Clinical Practice Abstract  similar documents
S. R. Gilyarevskiy
 
Vol 16, No 6 (2020) An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? Abstract  similar documents
T. V. Pavlova
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
 
Vol 16, No 3 (2020) Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue Abstract  similar documents
O. D. Ostroumova, I. V. Goloborodova
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract  similar documents
Company Pfizer
 
Vol 15, No 3 (2019) Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population Abstract  similar documents
K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev
"... », «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 16, No 5 (2020) New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants Abstract  PDF (Eng)  similar documents
K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
"... of nucleotide sequence showed significant deviation: 4 in the ABCG2 gene, 2 in the CYP3A4 gene, and 1 ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..."
 
Vol 16, No 2 (2020) The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment Abstract  similar documents
К. V. Lobastov, I. V. Schastlivtsev
"... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..."
 
Vol 16, No 4 (2020) The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? Abstract  similar documents
S. Yu. Martsevich
"... is inferior to apixaban in its ability to prevent ischemic stroke and systemic embolism and is more likely ..."
 
Vol 6, No 4 (2010) CLOPIDOGREL PHARMACOGENETICS Abstract  similar documents
A. N. Meshkov
"... of clopidogrel play an important role in the resistance development. Allel variants of the gene cytochrome CYP2C ..."
 
Vol 9, No 4 (2013) THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE Abstract  similar documents
K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev
"... The clinical significance  of CYP2C19 genetic polymorphism, associated with the violation ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 14, No 5 (2018) Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case Abstract  similar documents
M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov
"... therapy in this patient, namely, the  carriage of polymorphic markers  of the  ABCB1 CT, CES1 CA and  CYP3 ..."
 
Vol 6, No 4 (2010) ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? Abstract  similar documents
S. J. Martsevich
 
Vol 14, No 4 (2018) Role of Single Nucleotide Polymorphism of СУР17А Gene in the Development of Stroke Abstract  similar documents
S. Yu. Nikulina, V. A. Shulman, A. A. Chernova, D. A. Nikulin, A. A. Semenchukov, O. V. Marilovceva, S. S. Tret'jakova, I. I. Lebedeva, V. N. Maksimov
"...  CYP17A1 is one of the many genes that can participate in the formation of predisposition ..."
 
Vol 11, No 4 (2015) INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION Abstract  PDF (Eng)  similar documents
K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev
"... Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation ..."
 
Vol 13, No 6 (2017) CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE Abstract  similar documents
A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina
"... Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization ..."
 
Vol 14, No 1 (2018) NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME Abstract  similar documents
K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev
"... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..."
 
Vol 15, No 5 (2019) Findings Released from NAXOS Analysis. Pfizer Company Press Release Abstract  similar documents
article Editorial
"... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..."
 
Vol 13, No 4 (2017) GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS Abstract  similar documents
M. A. Vorobyeva, M. M. Azova, O. O. Gigani, I. V. Garmash, S. V. Villevalde, Zh. D. Kobalava
"... , 62.1% of men) were included into the study. Polymorphism Phe189Ser of the CYP3A4 (gene encoding ..."
 
Vol 14, No 1 (2018) NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
Ju. P. Skirdenko, N. A. Nikolayev
"... , polymorphism of genes CYP2C9 and VKORC1 and the structure of food preferences. Results. Persons ..."
 
Vol 3, No 2 (2007) VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY Abstract  similar documents
D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes
"... of polymorphisms of genes of their biotransformation (CYP2C9) and molecule-targets (VKORC1). This created basis ..."
 
Vol 12, No 5 (2016) Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms Abstract  PDF (Eng)  similar documents
Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev
"... Aim. To evaluate treatment adherence and prevalence of CYP2C9 and VKORC1 gene mutations ..."
 
Vol 9, No 5 (2013) APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA Abstract  similar documents
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..."
 
Vol 16, No 1 (2020) Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients Abstract  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
"... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 15, No 6 (2019) Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) Abstract  similar documents
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..."
 
Vol 12, No 5 (2016) Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention Abstract  similar documents
E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva
"... and laboratory biomarkers were assessed before stenting, as well as CYP2C19 genotyping after patient’s discharge ..."
 
Vol 16, No 2 (2020) Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation Abstract  similar documents
Yu. P. Skirdenko, N. A. Nikolaev
"... of CYP2C9 and VKORC1 genes mutations were determined at the initial examination. These indicators were ..."
 
1 - 64 of 64 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)